This $676,147 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a research initiative led by Harvard University to develop data-driven biomarker-informed decision analytics to improve the efficacy and reduce the toxicity of immune checkpoint blockade therapy for melanoma patients. The 3-year project aims to leverage advanced analytics and biomarker data to optimize the use of this cutting-edge cancer immunotherapy, with the goal of enhancing treatment outcomes and minimizing side effects. As a prestigious research university, Harvard has a strong track record of federal grant funding and innovative medical research. This award demonstrates the federal government's commitment to advancing melanoma treatment through collaborative, multidisciplinary efforts between academic and defense research institutions.
Generated 1/28/25, 9:57 AM